

REMARKSIntroductory Comments:

Claims 1-56 were examined in the Office Action dated December 15, 2006.

Claims 1, 23, and 34 were rejected under 35 U.S.C. §112 as allegedly not enabled.

Claims 2, 3, 9, 18, 24, 26, 28, 29, 39, and 4I were objected to for being dependent on rejected base claims.

Claims 2, 3, 9, 18, 24, 26, 28, 29, 39, and 4I were said to contain allowable subject matter.

SUPPORT FOR AMENDMENTS

Claims 1, 23, 34, and 45 have been recited that the compound is Pro28-amide, Pro29-amide, Pro33-amide, Pro34-amide, Pro35-amide, or Pro36-amide. The amendment finds support throughout the specification including Figure 6.

Claims 3-8, 10-17, 19-22, 24-33, 35-38, 40, 42-44, and 50-56 have been canceled without prejudice. Applicants reserve the right to pursue the canceled subject matter in one or more related divisional, continuation, or continuation-in-part applications.

Accordingly, no new matter has been added by way of this amendment and the entry thereof is respectfully requested.

Addressing the Examiner's Rejections**Rejections of the Claims Under 35 U.S.C. §112**

The Examiner rejected claims 1, 23, and 34 under 35 U.S.C. §112 as allegedly not enabled. In order to further prosecution, the applicants have amended the claims to recite a compound that is Pro28-amide, Pro29-amide, Pro33-amide, Pro34-amide, Pro35-amide, or Pro36-amide. As acknowledged by the Examiner, these amended claims are enabled. Therefore, the Examiner is requested to withdraw the rejection.

Allowable Subject Matter

The Examiner indicated that the invention of claims 2, 3, 9, 18, 23, 24, 26, 28, 29, 34, 39, and 41 was allowable if the nonelected subject matter was canceled. The applicants have amended the independent claims as suggested by the Examiner.

CONCLUSION

The claims pertain to patentable subject matter, and a notice of allowance is earnestly solicited. If the Examiner has any questions concerning this Response, the Examiner is invited to telephone Applicants' representative at (650) 335-7818.

Respectfully submitted,
Sharat Singh *et al.*

Dated: June 7, 2007

By: /Narinder Banait/
Narinder S. Banait, Reg. No. 43,482
Fenwick & West LLP
801 California Street
Mountain View, CA 94041
Telephone: 650-335-7818
Facsimile: 650-938-5200
E-mail: nbanait@fenwick.com